Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Clinical Significance of Combining Preoperative and Postoperative Albumin-Bilirubin Score in Colorectal Cancer: Doyoun Kim, Jae-Hoon Lee, Eun-Suk Cho, Su-Jin Shin, Hye Sun Lee, Hwa-Hee Koh, Kang Young Lee, Jeonghyun Kang; Cancer Res Treat. 2023;55(4):1261-1269. Published online April 17, 2023; DOI: https://doi.org/10.4143/crt.2022.1444

Abstract PDF Supplementary Material PubReader ePub

Purpose
Albumin-bilirubin (ALBI) score is a well-known prognostic factor for various diseases, including colorectal cancer (CRC). However, little is known about the significance of postoperative ALBI score changes in patients with CRC.
Materials and Methods
A total of 723 patients who underwent surgery were enrolled. Preoperative ALBI (ALBI-pre) and postoperative ALBI (ALBI-post) scores were divided into low and high score groups. ALBI-trend was defined as a combination of four groups comprising the low and high ALBI-pre and ALBI-post score groups. Kaplan-Meier survival curves were used to compare the overall survival (OS) between the different ALBI groups. The Cox proportional hazards model was used to examine the independent relevant factors of OS. Stratification performance was compared between the different ALBI groupings using Harrell’s concordance index (C-index).
Results
ALBI-pre, ALBI-post, and ALBI-trend score groups were significant prognostic factors of OS in the univariable analysis. However, multivariable analysis showed that ALBI-trend was an independent prognostic factor while ALBI-pre and ALBI-post were not. The C-index of ALBI-trend (0.622; 95% confidence interval [CI], 0.587 to 0.655) was higher than that of ALBI-pre (0.589; 95% CI, 0.557 to 0.621; bootstrap mean difference, 0.033; 95% CI, 0.013 to 0.057) and ALBI-post (0.575; 95% CI, 0.545 to 0.605; bootstrap mean difference, 0.047; 95% CI, 0.024 to 0.074).
Conclusion
Combining ALBI-pre and ALBI-post scores is an independent prognostic factor of OS and shows superior predictive power compared to ALBI-pre or ALBI-post alone in patients with CRC.

Citations

Citations to this article as recorded by

Comparing laboratory toxicity of selective intra-arterial radionuclide therapy for primary and metastatic liver tumors: resin versus glass microspheres
Başak Soydaş-Turan, M. Fani Bozkurt, Gonca Eldem, Bora Peynircioglu, Omer Ugur, Bilge Volkan-Salanci
Annals of Nuclear Medicine.2025; 39(4): 373. CrossRef
Improvement of Hypoalbuminemia and Hepatic Reserve after Stent Placement for Postsurgical Portal Vein Stenosis
Naoya Kinota, Daisuke Abo, Ryo Morita, Koji Yamasaki, Takaaki Fujii, Daisuke Kato, Tasuku Kimura, Yusuke Sakuhara, Kazufumi Okada, Isao Yokota, Tatsuya Orimo, Tatsuhiko Kakisaka, Toru Nakamura, Satoshi Hirano, Kazuyuki Minowa, Kohsuke Kudo
Journal of Vascular and Interventional Radiology.2025; 36(4): 616. CrossRef
Gastrointestinal tumors of the small bowel: prognostic roles of tumor stage and inflammatory markers
Mehmet Torun, Sevil Özkan, Deniz Kol Özbay, Erkan Özkan
Anatolian Current Medical Journal.2025; 7(2): 164. CrossRef
Assessment of the albumin-bilirubin score in breast cancer patients with liver metastasis after surgery
Li Chen, Chunlei Tan, Qingwen Li, Zhibo Ma, Meng Wu, Xiaosheng Tan, Tiangen Wu, Jinwen Liu, Jing Wang
Heliyon.2023; 9(11): e21772. CrossRef

3,648 View
182 Download
3 Web of Science
4 Crossref

Breast cancer

Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study: Wei Ren, Yunfang Yu, Huangming Hong, Ying Wang, Quanlong Gao, Yongjian Chen, Peixian Chen, Jianli Zhao, Qiyun Ou, Dagui Lin, Tuping Fu, Yujie Tan, Chenchen Li, Xinxin Xie, Guolin Ye, Jun Tang, Herui Yao; Cancer Res Treat. 2022;54(4):1038-1052. Published online February 4, 2022; DOI: https://doi.org/10.4143/crt.2021.698

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aims to comprehensively evaluate the clinical efficacy of chemotherapy or endocrine therapy maintenance in metastatic breast cancer (MBC) patients.
Materials and Methods
The meta-analysis of randomized clinical trials (RCTs) and propensity score matching of multicenter cohort study evaluated MBC patients who underwent first-line chemotherapy or endocrine therapy maintenance. This study is registered with PROSPERO: CRD42017071858 and ClinicalTrials.gov: NCT04258163.
Results
A total of 2,867 patients from 15 RCTs and 760 patients from multicenter cohort were included. The results from meta-analysis showed that chemotherapy maintenance improved progression-free survival (PFS) (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.54 to 0.73; p < 0.001; moderate-quality evidence) and overall survival (OS) (HR, 0.87; 95% CI 0.78 to 0.97; p=0.016; high-quality evidence) than observation. In the cohort study, for hormone receptor–positive MBC patients, chemotherapy maintenance improved PFS (HR, 0.67; 95% CI, 0.52 to 0.85; p < 0.001) and OS (HR, 0.55; 95% CI 0.42 to 0.73; p < 0.001) compared with observation, and endocrine therapy maintenance also improved PFS (HR, 0.65; 95% CI, 0.53 to 0.80; p < 0.001) and OS (HR, 0.55; 95% CI, 0.44 to 0.69; p < 0.001). There were no differences between chemotherapy and endocrine therapy maintenance in PFS and OS (all p > 0.05). Regardless of the continuum or switch maintenance therapy, showed prolonged survival in MBC patients who were response to first-line treatment.
Conclusion
This study provided evidences for survival benefits of chemotherapy and endocrine therapy maintenance in MBC patients, and there was no difference efficacy between chemotherapy and endocrine therapy maintenance for hormone receptor–positive patients.

Citations

Citations to this article as recorded by

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
Fatima Cardoso, Shani Paluch-Shimon, Eva Schumacher-Wulf, Leonor Matos, Karen Gelmon, Matti S. Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chavez-MacGregor,
The Breast.2024; 76: 103756. CrossRef
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer
Stanislas Quesada, William Jacot
The Lancet Oncology.2022; 23(5): 557. CrossRef

6,110 View
162 Download
2 Web of Science
2 Crossref

The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12): Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim; Cancer Res Treat. 2022;54(4):1121-1129. Published online December 31, 2021; DOI: https://doi.org/10.4143/crt.2021.1083

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods
We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results
Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion
The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Citations

Citations to this article as recorded by

Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C
Breast Cancer Research and Treatment.2023; 200(1): 37. CrossRef

6,729 View
186 Download
1 Web of Science
1 Crossref

Lung and Thoracic cancer

Clinical Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials: Qing Yin, Longguo Dai, Ruizhu Sun, Ping Ke, Liya Liu, Bo Jiang; Cancer Res Treat. 2022;54(3):803-816. Published online October 25, 2021; DOI: https://doi.org/10.4143/crt.2021.764

Abstract PDF Supplementary Material PubReader ePub

Purpose
This network meta-analysis (NMA) was conducted to compare the efficacy of immune checkpoint inhibitors in advanced non–small cell lung cancer (NSCLC) patients with liver metastases.
Materials and Methods
English literature was retrieved from the PubMed, American Society of Clinical Oncology, and European Society for Medical Oncology databases from January 2015 to January 2021. We pooled the overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) using an NMA and ranked treatments by the surface under the cumulative ranking curve. Publication bias was evaluated by Begg’s and Egger’s tests. STATA 15.0 was used for the sensitivity analysis, and the remaining statistical analyses were performed using R 4.0.2.
Results
Nine eligible phase III randomized controlled trials were included, including 1,141 patients with liver metastases. Pembrolizumab+chemotherapy ranked highest, followed by atezolizumab+bevacizumab+chemotherapy and nivolumab. However, no significant difference in OS rates was observed across these three treatments (HR, 0.98; 95% confidence interval [CI], 0.43 to 2.22 for pembrolizumab+chemotherapy vs. atezolizumab+bevacizumab+chemotherapy; HR, 0.91; 95% CI, 0.52 to 1.57 for pembrolizumab+chemotherapy vs. nivolumab). Regarding the PFS rate, atezolizumab+bevacizumab+chemotherapy and pembro-lizumab+chemotherapy ranked highest and no significant difference was observed between them (HR, 0.79; 95% CI, 0.36 to 1.70 for atezolizumab+bevacizumab+chemotherapy vs. pembrolizumab+chemotherapy).
Conclusion
Pembrolizumab+chemotherapy, atezolizumab+bevacizumab+chemotherapy, and nivolumab were superior to other treatments in NSCLC patients with liver metastases. These new findings may help clinicians better select therapeutic strategies for NSCLC patients with liver metastases.

Citations

Citations to this article as recorded by

The Mechanism of Lactic Acid Regulating Platelet-Derived Microparticles to Affect the Biological Characteristics of Human Lung Adenocarcinoma
红艳刘
Advances in Clinical Medicine.2025; 15(01): 274. CrossRef
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases
Fan-jie Qu, Yi Zhou, Shuang Wu
British Journal of Cancer.2024; 130(2): 165. CrossRef
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
Daisuke Hazama, Kenji Nakahama, Hiroaki Kodama, Akito Miyazaki, Koichi Azuma, Yosuke Kawashima, Yuki Sato, Kentaro Ito, Yoshimasa Shiraishi, Keita Miura, Takayuki Takahama, Satoshi Oizumi, Yoshinobu Namba, Satoshi Ikeda, Hiroshige Yoshioka, Asuka Tsuya, Y
JTO Clinical and Research Reports.2024; 5(1): 100613. CrossRef
Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer
Lingling Zhu, Xianzhe Yu, Xiaojun Tang, Chenggong Hu, Lei Wu, Yanyang Liu, Qinghua Zhou
Chinese Medical Journal.2024; 137(9): 1019. CrossRef
Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases
Vesna Ćeriman Krstić, Natalija Samardžić, Milija Gajić, Milan Savić, Biljana Šeha, Marina Roksandić Milenković, Dragana Jovanović
Current Issues in Molecular Biology.2024; 46(12): 13443. CrossRef
Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis
Huilin Xu, Pingpo Ming, Zhenyu Zhao, Nan Zhao, Dingjie Zhou, Xixian Tang, Dedong Cao
Integrative Cancer Therapies.2023;[Epub] CrossRef
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
Handai Xia, Wengang Zhang, Yuqing Zhang, Xiaoling Shang, Yanguo Liu, Xiuwen Wang
Frontiers in Oncology.2022;[Epub] CrossRef

8,138 View
258 Download
7 Web of Science
7 Crossref

The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer: Yu Feng, Yutao Liu, Mingming Yuan, Guilan Dong, Hongxia Zhang, Tongmei Zhang, Lianpeng Chang, Xuefeng Xia, Lifeng Li, Haohua Zhu, Puyuan Xing, Hongyu Wang, Yuankai Shi, Zhijie Wang, Xingsheng Hu; Cancer Res Treat. 2022;54(3):753-766. Published online October 5, 2021; DOI: https://doi.org/10.4143/crt.2021.905

Abstract PDF Supplementary Material PubReader ePub

Purpose
To investigate the feasibility of biomarkers based on dynamic circulating tumor DNA (ctDNA) to classify small cell lung cancer (SCLC) into different subtypes.
Materials and Methods
Tumor and longitudinal plasma ctDNA samples were analyzed by next-generation sequencing of 1,021 genes. PyClone was used to infer the molecular tumor burden index (mTBI). Pre-treatment tumor tissues [T1] and serial plasma samples were collected (pre-treatment [B1], after two [B2], six [B3] cycles of chemotherapy and at progression [B4]).
Results
Overall concordance between T1 and B1 sequencing (n=30) was 66.5%, and 89.5% in the gene of RB1. A classification method was designed according to the changes of RB1 mutation, named as subtype Ⅰ (both positive at B1 and B2), subtype Ⅱ (positive at B1 but negative at B2), and subtype Ⅲ (both negative at B1 and B2). The median progressive-free survival for subtype Ⅰ patients (4.5 months [95%CI: 2.6-5.8]) was inferior to subtype Ⅱ (not reached, p<0.0001) and subtype Ⅲ (10.8 months [95%CI: 6.0-14.4], p=0.002). The median overall survival for subtype Ⅰ patients (16.3 months [95%CI: 5.3-22.9]) was inferior to subtype Ⅱ (not reached, p=0.01) and subtype Ⅲ (not reached, p=0.02). Patients with a mTBI dropped to zero at B2 had longer median overall survival (not reached vs. 19.5 months, p=0.01). The changes of mTBI from B4 to B1 were sensitive to predict new metastases, with a sensitivity of 100% and a specificity of 85.7%.
Conclusion
Monitoring ctDNA based RB1 mutation and mTBI provided a feasible tool to predict the prognosis of SCLC.

Citations

Citations to this article as recorded by

Cell-free and extrachromosomal DNA profiling of small cell lung cancer
Roya Behrouzi, Alexandra Clipson, Kathryn L. Simpson, Fiona Blackhall, Dominic G. Rothwell, Caroline Dive, Florent Mouliere
Trends in Molecular Medicine.2025; 31(1): 64. CrossRef
Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration
Changshu Li, Jun Shao, Peiyi Li, Jiaming Feng, Jingwei Li, Chengdi Wang
Cancer Letters.2023; 577: 216365. CrossRef
Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients
Fan Yang, Min Tang, Liang Cui, Jing Bai, Jiangyong Yu, Jiayi Gao, Xin Nie, Xu Li, Xuefeng Xia, Xin Yi, Ping Zhang, Lin Li
Thoracic Cancer.2023; 14(31): 3097. CrossRef
Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets
Ugo Testa, Elvira Pelosi, Germana Castelli
Onco.2022; 2(3): 186. CrossRef

7,114 View
201 Download
4 Web of Science
4 Crossref

Hematologic malignancy

Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study: Yu Ri Kim, Soo-Jeong Kim, Hye Sun Lee, Soyoung Jeon, Hyunsoo Cho, Haerim Chung, Ji Eun Jang, June-Won Cheong, Yoo Hong Min, Jin Seok Kim; Cancer Res Treat. 2022;54(2):613-620. Published online August 5, 2021; DOI: https://doi.org/10.4143/crt.2021.270

Abstract PDF PubReader ePub

Purpose
Event-free survival at 24 months (EFS24) is known to be a surrogate marker for overall survival (OS) for patients with peripheral T-cell lymphoma (PTCL). We examined the role of EFS24 in PTCL compared to diffuse large B-cell lymphoma (DLBCL), and then assessed the clinical predictive factors of achieving EFS24.
Materials and Methods
Patients with newly diagnosed PTCL treated with anthracycline-based chemotherapy were included. Subsequent OS was defined as the time elapsed from 24 months after diagnosis until death from any cause in those who achieved EFS24.
Results
Overall, 153 patients were evaluated, and 51 patients (33.3%) achieved EFS24. Patients who achieved EFS24 showed superior OS compared to patients who did not (p < 0.001). EFS24 could stratify the subsequent OS although it did not reach to that of the general population. After matching the PTCL group to the DLBCL group based on the international prognostic index, the subsequent OS in patients who achieved EFS24 was similar between the two groups (p=0.094). Advanced stage was a significant factor to predict the failing EFS24 by multivariable analysis (p < 0.001).
Conclusion
Patients with PTCL who achieve EFS24 could have a favorable subsequent OS. Since advanced disease stage is a predictor of EFS24 failure, future efforts should focus on developing novel therapeutic strategies for PTCL patients presenting with advanced disease.

Citations

Citations to this article as recorded by

Prognostic impact of pre-treatment and post-treatment plasma Epstein-Barr virus DNA in peripheral T-cell lymphomas
Chu-Yi Chan, Tung-Liang Lin, Ming-Chung Kuo, Yu-Shin Hung, Hung Chang, Che-Wei Ou, Jin-Hou Wu, Hsuan-Jen Shih, Yi-Jiun Su, Lee-Yung Shih, Yuen-Chin Ong, Wen-Yu Chuang, Hsiao-Wen Kao
Annals of Medicine.2025;[Epub] CrossRef
Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS
Zheng Cao, Xiaojun Wang, Xuemin Xue, Xiaoli Feng
Annals of Hematology.2024; 103(3): 869. CrossRef
Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments
Sarit Assouline, Adriana Wiesinger, Clare Spooner, Jelena Jovanović, Max Schlueter
Critical Reviews in Oncology/Hematology.2022; 175: 103711. CrossRef

6,259 View
138 Download
4 Web of Science
3 Crossref

Gynecologic cancer

Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival: Kyoung Won Noh, Bomi Kim, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Won Kyung Cho, Won Park, Yoo-Young Lee; Cancer Res Treat. 2022;54(1):245-252. Published online April 15, 2021; DOI: https://doi.org/10.4143/crt.2021.023

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the effect of waiting time, from diagnosis to initiation of definitive concurrent chemoradiation (CCRT), on overall survival in cervical cancer patients.
Materials and Methods
Patients with cervical cancer who were treated with definitive CCRT between 2000 and 2017 were retrospectively reviewed. Time from initial pathological diagnosis to definitive CCRT was analyzed both as a continuous variable (per day) and as a categorical variable in two groups (group 1 ≤ median, group 2 > median). Patients with a waiting time of more than 60 days were excluded.
Results
The median waiting time was 14 days (0-60). There were differences between group 1 and group 2 in age and chemotherapy regimens. However, no significant difference was found in the International Federation of Gynecology and Obstetrics stage, cell type, or the number of cycles of chemotherapy received during CCRT. A longer waiting time was associated with poorer overall survival on the Kaplan-Meier curve (group 1 vs. group 2, p=0.042). On multivariate analysis, intervals as either a continuous variable (hazard ratio [HR], 1.023; 95% confidence interval [CI], 1.006 to 1.040; p=0.007) or a categorical variable (HR, 1.513; 95% CI, 1.073 to 2.134; p=0.018), FIGO stage, cell type, and the number of cycles of chemotherapy received during CCRT were significant independent prognostic factors for overall survival.
Conclusion
A shorter waiting time from pathological diagnosis to definitive CCRT showed benefit on overall survival. Our findings suggest that an effort to minimize waiting times should be recommended in cervical cancer patients who are candidates for CCRT.

Citations

Citations to this article as recorded by

Effect of waiting time for radiotherapy after last induction chemotherapy on prognosis of locally advanced nasopharyngeal carcinoma
Kui‐Xuan Zhu, Ting Ding, Yi‐Min E, Hong‐Wei Yang, Rui‐Ping Wu, Run‐Jia Liu, Ling‐Li Zhou, Wen‐Jie Fu, Mei‐Ping Jiang, Xiao‐Li Wang
Head & Neck.2024; 46(5): 1189. CrossRef
An Innovative Thermal Imaging Prototype for Precise Breast Cancer Detection: Integrating Compression Techniques and Classification Methods
Khaled S. Ahmed, Fayroz F. Sherif, Mohamed S. Abdallah, Young-Im Cho, Shereen M. ElMetwally
Bioengineering.2024; 11(8): 764. CrossRef
Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study
Amy P. Hack, Ronald P. Zweemer, Trudy N. Jonges, Femke van der Leij, Cornelis G. Gerestein, Max Peters, Ina M. Jürgenliemk-Schulz, Peter S.N. van Rossum
Gynecologic Oncology.2022; 165(2): 339. CrossRef
The Role of Conization before Radical Hysterectomy in Cervical Cancer including High Risk Factors of Recurrence: Propensity Score Matching
Chi-Son Chang, Ji Song Min, Ki Hyeon Song, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Yoo-Young Lee
Cancers.2022; 14(16): 3863. CrossRef
Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study
Yu Min, Zheran Liu, Rendong Huang, Ruidan Li, Jing Jin, Zhigong Wei, Ling He, Yiyan Pei, Ning Li, Yongllin Su, Xiaolin Hu, Xingchen Peng
Journal of Translational Medicine.2022;[Epub] CrossRef

7,133 View
195 Download
7 Web of Science
5 Crossref

Gastrointestinal cancer

An Innovative Prognostic Model Based on Four Genes in Asian Patient with Gastric Cancer: Jiahui Chen, Anqiang Wang, Jun Ji, Kai Zhou, Zhaode Bu, Guoqing Lyu, Jiafu Ji; Cancer Res Treat. 2021;53(1):148-161. Published online August 31, 2020; DOI: https://doi.org/10.4143/crt.2020.424

Abstract PDF Supplementary Material PubReader ePub

Purpose
Gastric cancer (GC) has substantial biological differences between Asian and non-Asian populations, which makes it difficult to have a unified predictive measure for all people. We aimed to identify novel prognostic biomarkers to help predict the prognosis of Asian GC patients.
Materials and Methods
We investigated the differential gene expression between GC and normal tissues of GSE66229. Univariate, multivariate and Lasso Cox regression analyses were conducted to establish a four-gene-related prognostic model based on the risk score. The risk score was based on a linear combination of the expression levels of individual genes multiplied by their multivariate Cox regression coefficients. Validation of the prognostic model was conducted using The Cancer Genome Atlas (TCGA) database. A nomogram containing clinical characteristics and the prognostic model was established to predict the prognosis of Asian GC patients.
Results
Four genes (RBPMS2, RGN, PLEKHS1, and CT83) were selected to establish the prognostic model, and it was validated in the TCGA Asian cohort. Receiver operating characteristic analysis confirmed the sensitivity and specificity of the prognostic model. Based on the prognostic model, a nomogram containing clinical characteristics and the prognostic model was established, and Harrell’s concordance index of the nomogram for evaluating the overall survival significantly higher than the model only focuses on the pathologic stage (0.74 vs. 0.64, p < 0.001).
Conclusion
The four-gene-related prognostic model and the nomogram based on it are reliable tools for predicting the overall survival of Asian GC patients.

Citations

Citations to this article as recorded by

Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial
Jing Wu, Shilong Zhang, Shan Yu, Guo An, Yi Wang, Yiyi Yu, Li Liang, Yan Wang, Xiaojing Xu, YanShi Xiong, Di Shao, Zhun Shi, Nannan Li, Jingyuan Wang, Dawei Jin, Tianshu Liu, Yuehong Cui
Nature Communications.2024;[Epub] CrossRef
An integrated analysis of prognostic mRNA signature in early- and progressive-stage gastric adenocarcinoma
Xiaoling Hong, Kai Zhuang, Na Xu, Jiang Wang, Yong Liu, Siqi Tang, Junzhang Zhao, Zunnan Huang
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
Analysis and application of RNA binding protein gene pairs to predict the prognosis of gastric cancer
Zhi-kun Ning, Hua-kai Tian, Jiang Liu, Ce-gui Hu, Zi-tao Liu, Hui Li, Zhen Zong
Heliyon.2023; 9(7): e18242. CrossRef
PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate
Tamara A.M. Chessa, Piotr Jung, Arqum Anwar, Sabine Suire, Karen E. Anderson, David Barneda, Anna Kielkowska, Barzan A. Sadiq, Ieng Wai Lai, Sergio Felisbino, Daniel J. Turnham, Helen B. Pearson, Wayne A. Phillips, Junko Sasaki, Takehiko Sasaki, David Oxl
Molecular Cell.2023; 83(16): 2991. CrossRef
Evaluation of vital genes correlated with CD8 + T cell infiltration as prognostic biomarkers in stomach adenocarcinoma
Dun Pan, Hui Chen, Jiaxiang Xu, Xin Lin, Liangqing Li
BMC Gastroenterology.2023;[Epub] CrossRef
Bayesian hierarchical lasso Cox model: A 9-gene prognostic signature for overall survival in gastric cancer in an Asian population
Jiadong Chu, Na Sun, Wei Hu, Xuanli Chen, Nengjun Yi, Yueping Shen, Andy T. Y. Lau
PLOS ONE.2022; 17(4): e0266805. CrossRef
Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
Ya Guo, Yin Bin Zhang, Yi Li, Wang Hui Su, Shan He, Shu Pei Pan, Kun Xu, Wei Hua Kou, Luca Falzone
International Journal of Genomics.2022; 2022: 1. CrossRef
KK-LC-1 may be an effective prognostic biomarker for gastric cancer
Jun Ji, Jiahui Chen, Anqiang Wang, Wei Zhang, Hongge Ju, Yang Liu, Leping Li
BMC Cancer.2021;[Epub] CrossRef
Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer
Chen Chen, Dan Gao, Jinlong Huo, Rui Qu, Youming Guo, Xiaochi Hu, Libo Luo
Scientific Reports.2021;[Epub] CrossRef
Integrative analysis-based identification and validation of a prognostic immune cell infiltration-based model for patients with advanced gastric cancer
Siwei Pan, Qi Gao, Qingchuan Chen, Pengfei Liu, Yuen Tan, Funan Liu, Huimian Xu
International Immunopharmacology.2021; 101: 108258. CrossRef

9,198 View
184 Download
12 Web of Science
10 Crossref

High Systemic Inflammation Response Index (SIRI) Indicates Poor Outcome in Gallbladder Cancer Patients with Surgical Resection: A Single Institution Experience in China: Lejia Sun, Wenmo Hu, Meixi Liu, Yang Chen, Bao Jin, Haifeng Xu, Shunda Du, Yiyao Xu, Haitao Zhao, Xin Lu, Xinting Sang, Shouxian Zhong, Huayu Yang, Yilei Mao; Cancer Res Treat. 2020;52(4):1199-1210. Published online July 21, 2020; DOI: https://doi.org/10.4143/crt.2020.303

Abstract PDF PubReader ePub

Purpose
The systemic inflammation response index (SIRI) has been reported to have prognostic ability in various solid tumors but has not been studied in gallbladder cancer (GBC). We aimed to determine its prognostic value in GBC.
Materials and Methods
From 2003 to 2017, patients with confirmed GBC were recruited. To determine the SIRI’s optimal cutoff value, a time-dependent receiver operating characteristic curve was applied. Univariate and multivariate Cox analyses were performed for the recognition of significant factors. Then the cohort was randomly divided into the training and the validation set. A nomogram was constructed using the SIRI and other selected indicators in the training set, and compared with the TNM staging system. C-index, calibration plots, and decision curve analysis were performed to assess the nomogram’s clinical utility.
Results
One hundred twenty-four patients were included. The SIRI’s optimal cutoff value divided patients into high (≥ 0.89) and low SIRI (< 0.89) groups. Kaplan-Meier curves according to SIRI levels were significantly different (p < 0.001). The high SIRI group tended to stay longer in hospital and lost more blood during surgery. SIRI, body mass index, weight loss, carbohydrate antigen 19-9, radical surgery, and TNM stage were combined to generate a nomogram (C-index, 0.821 in the training cohort, 0.828 in the validation cohort) that was significantly superior to the TNM staging system both in the training (C-index, 0.655) and validation cohort (C-index, 0.649).
Conclusion
The SIRI is an independent predictor of prognosis in GBC. A nomogram based on the SIRI may help physicians to precisely stratify patients and implement individualized treatment.

Citations

Citations to this article as recorded by

SIRI and SII as potential biomarkers of disease activity and lupus nephritis in systemic lupus erythematosus
Chi-Hui Yang, Xin-Yi Wang, Yi-Hui Zhang, Ning Ding
Frontiers in Immunology.2025;[Epub] CrossRef
Systemic inflammatory response index as a novel biomarker for age-related macular degeneration: a cross-sectional study from NHANES (2005–2008)
Ruoshuang Jia, Yiqing Yin, Huimin Shan
Frontiers in Nutrition.2025;[Epub] CrossRef
Combining systemic inflammatory response index and albumin fibrinogen ratio to predict early serious complications and prognosis after resectable gastric cancer
Jing-Yao Ren, Da Wang, Li-Hui Zhu, Shuo Liu, Miao Yu, Hui Cai
World Journal of Gastrointestinal Oncology.2024; 16(3): 732. CrossRef
Association of Systemic Inflammation Response Index with Short-Term All-Cause Mortality in Decompensated Liver Cirrhosis Patients
Jin Cheng, Honglei Ju, Guixiang Wang, Chiyi He, Wei Wang
Journal of Inflammation Research.2024; Volume 17: 8985. CrossRef
Advances in the Study of the Relationship between Inflammation Markers and Post-Stroke Depression
颖张
Advances in Clinical Medicine.2024; 14(12): 7. CrossRef
The systemic inflammation response index as a significant predictor of short-term adverse outcomes in acute decompensated heart failure patients: a cohort study from Southern China
Lin Xie, Qun Wang, Hengcheng Lu, Maobin Kuang, Shiming He, Guobo Xie, Guotai Sheng, Shuhua Zhang, Wei Wang, Yang Zou
Frontiers in Endocrinology.2024;[Epub] CrossRef
The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma
Tian Wang, Duo Zhang, Di Tang, Yu Heng, Li-ming Lu, Lei Tao
Journal of Cancer Research and Clinical Oncology.2023; 149(9): 5627. CrossRef
Preoperative Fibrinogen Albumin Ratio is an Effective Biomarker for Prognostic Evaluation of Gallbladder Carcinoma After Radical Resection: A 10-Year Retrospective Study at a Single Center
Qi Li, Jian Zhang, Qi Gao, Jialu Fu, Mengke Li, Hengchao Liu, Chen Chen, Dong Zhang, Zhimin Geng
Journal of Inflammation Research.2023; Volume 16: 677. CrossRef
Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation
Songping Cui, Shuang Cao, Qing Chen, Qiang He, Ren Lang
Frontiers in Immunology.2023;[Epub] CrossRef
Assessment of aggregate index of systemic inflammation and systemic inflammatory response index in dry age-related macular degeneration: a retrospective study
Naif S. Sannan
Frontiers in Medicine.2023;[Epub] CrossRef
Value of preoperative systemic inflammatory response index and prognostic nutritional index in predicting prognosis of patients with superficial esophageal squamous cell carcinoma
Jing Wang, Xue-Li Ding, Zi-Bin Tian
World Chinese Journal of Digestology.2023; 31(9): 369. CrossRef
The Prognostic Value and Potential Mechanism of Tumor-Nutrition-Inflammation Index and Genes in Patients with Advanced Lung Cancer
Huan Wang, Yuting Shi, Yueli Shi, Mengqing Cao, Long Zhang, Yuan Wu, Yun Xu, Kai Wang, Xianwu Weng, Bing Niu
International Journal of Clinical Practice.2023; 2023: 1. CrossRef
The Potential Value of Systemic Inflammation Response Index on Delirium After Hip Arthroplasty Surgery in Older Patients: A Retrospective Study
Wenbin Lu, Shengwei Lin, Cheng Wang, Peipei Jin, Jinjun Bian
International Journal of General Medicine.2023; Volume 16: 5355. CrossRef
Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs
Shun Jiang, Sisi Wang, Qianqian Wang, Chao Deng, Yuhua Feng, Fang Ma, Jin'an Ma, Xianling Liu, Chunhong Hu, Tao Hou
Cancer Management and Research.2021; Volume 13: 1315. CrossRef
The Prognostic Value of Preoperative Systemic Inflammatory Response Index (SIRI) in Patients With High-Grade Glioma and the Establishment of a Nomogram
Qian He, Longhao Li, Qinglan Ren
Frontiers in Oncology.2021;[Epub] CrossRef
Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
Yu-Jia Shen, Li-Qiang Qian, Zheng-Ping Ding, Qing-Quan Luo, Heng Zhao, Wu-Yan Xia, Yuan-Yuan Fu, Wen Feng, Qin Zhang, Wen Yu, Xu-Wei Cai, Xiao-Long Fu
Frontiers in Oncology.2021;[Epub] CrossRef

9,696 View
115 Download
31 Web of Science
16 Crossref

Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases: Chao Lin, Xue-Song Sun, Sai-Lan Liu, Xiao-Yun Li, Nian Lu, Xin-Ling Li, Lin-Quan Tang, Ling Guo; Cancer Res Treat. 2020;52(3):855-866. Published online March 10, 2020; DOI: https://doi.org/10.4143/crt.2019.772

Abstract PDF PubReader ePub

Purpose
The prognosis of nasopharyngeal carcinoma (NPC) patients with parotid lymph node (PLN) metastasis remains unclear. This study was performed to investigate the prognostic significance and optimal staging category of PLN metastasis and develop a nomogram for estimating individual risk.
Materials and Methods
Clinical data of 7,084 non-metastatic NPC patients were retrospectively reviewed. Overall survival (OS) was the primary endpoint. A nomogram was established based on the Cox proportional hazards regression model. The accuracy and calibration ability of this nomogram was evaluated by C-index and calibration curves with bootstrap validation.
Result
Totally, 164/7,084 NPC patients (2.3%) presented with PLNs. Multivariate analyses showed that PLN metastasis was a negative prognostic factor for OS, progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRFS). Patients with PLN metastasis had a worse prognosis than N3 disease. Five independent prognostic factors were included in the nomogram, which showed a C-index of 0.743. The calibration curves for probability of 3- and 5-year OS indicated satisfactory agreement between nomogram-based prediction and actual observation. All results were confirmed in the validation cohort.
Conclusion
NPC patient with PLN metastasis had poorer survival outcome (OS, PFS, DMFS, and LRFS) than N3 disease. We developed a nomogram to provide individual prediction of OS for patients with PLN metastasis.

Citations

Citations to this article as recorded by

Risk factors analysis and nomogram for predicting recurrence in periocular basal cell carcinoma
Xincen Hou, Alexander C. Rokohl, Katharina Berndt, Senmao Li, Xiaojun Ju, Philomena A. Wawer Matos, Wanlin Fan, Ludwig M. Heindl
Canadian Journal of Ophthalmology.2025;[Epub] CrossRef
Advances in Nasopharyngeal Carcinoma Staging: from the 7th to the 9th Edition of the TNM System and Future Outlook
Binhao Wu, Xiaozhong Chen, Caineng Cao
Current Oncology Reports.2025; 27(3): 322. CrossRef
Treatment outcomes in nasopharyngeal carcinoma patients with parotid lymph node metastasis: An 11‐year experience at a tertiary cancer center
Linghui Yan, Yuhao Lin, Wenrong Lin, Jiabiao Hong, Muling Deng, Chuanben Chen, Zhaodong Fei, Jianming Ding
International Journal of Cancer.2025;[Epub] CrossRef
Analysis of patients with parotid recurrence after parotid-sparing IMRT for nasopharyngeal carcinoma: case series and review of the literature
Sezin Yuce Sari, Melek Tugce Yilmaz, Gozde Yazici, Sepideh Mohammadipour, Gokhan Ozyigit, Ibrahim Gullu, Mustafa Cengiz
Strahlentherapie und Onkologie.2024; 200(12): 1057. CrossRef
Nomogram Based on Liver Function Test Indicators for Survival Prediction in Nasopharyngeal Carcinoma Patients Receiving PD-1 Inhibitor Therapy
Lixia Liang, Yan Li, Yansui Hong, Tianxing Ji, Hao Chen, Zhifang Lin
Current Oncology.2023; 30(8): 7189. CrossRef
A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma
Wen Liu, Huilan Li, Hui Sheng, Xiaohua Liu, Peidong Chi, Xueping Wang, Minjie Mao
Advances in Therapy.2020; 37(10): 4280. CrossRef
Prognosis prediction signature of seven immune genes based on HPV status in cervical cancer
Qianqian Xia, Hua Jin, Xing Zhang, Wenjing Yan, Dan Meng, Bo Ding, Jian Cao, Dake Li, Shizhi Wang
International Immunopharmacology.2020; 88: 106935. CrossRef

15,265 View
127 Download
5 Web of Science
7 Crossref

General

Correlation of NUF2 Overexpression with Poorer Patient Survival in Multiple Cancers: Xiaodan Jiang, Yan Jiang, Senbiao Luo, Karthik Sekar, Clara Kai Ting Koh, Amudha Deivasigamani, Qingzhe Dong, Niankai Zhang, Shenling Li, Fengyun Hao, Brian Kim Poh Goh, London Lucien Ooi, Yu Wang, Kam Man Hui; Cancer Res Treat. 2021;53(4):944-961. Published online January 4, 2020; DOI: https://doi.org/10.4143/crt.2020.466

Abstract PDF Supplementary Material PubReader ePub

Purpose
NUF2 has been implicated in multiple cancers recently, suggesting NUF2 may play a role in the common tumorigenesis process. In this study, we aim to perform comprehensive meta-analysis of NUF2 expression in the cancer types included in the Cancer Genome Atlas (TCGA).
Materials and Methods
RNA-sequencing data in 31 cancer types in the TCGA data and 11 independent datasets were used to examine NUF2 expression. Silencing NUF2 using targeting shRNAs in hepatocellular carcinoma (HCC) cell lines was used to evaluate NUF2’s role in HCC in vitro and in vivo.
Results
NUF2 up-regulation is significantly observed in 23 out of the 31 cancer types in the TCGA datasets and validated in 13 major cancer types using 11 independent datasets. NUF2 overexpression was clinically important as high NUF2 was significantly associated with tumor stages in eight different cancers. High NUF2 was also associated with significantly poorer patient overall survival and disease-free survival in eight and six cancers, respectively. We proceeded to validate NUF2 overexpression and its negative association with overall survival at the protein level in an independent cohort of 40 HCC patients. Compared to the non-targeting controls, NUF2 knockdown cells showed significantly reduced ability to grow, migrate into a scratch wound and invade the 8 μm porous membrane in vitro. Moreover, NUF2 knockdown cells also formed significantly smaller tumors than control cells in mouse xenograft assays in vivo.
Conclusion
NUF2 up-regulation is a common feature of many cancers. The prognostic potential and functional impact of NUF2 up-regulation warrant further studies.

Citations

Citations to this article as recorded by

Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway
Meng Lv, Xiangrui Chen, Qiting Yang, Chushuan Huang, Yongbiao Lv, Tian Zhang, Junxiang Cai
Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub] CrossRef
PBK as a novel biomarker performed excellent diagnostic and prognostic value in HCC associated with immune infiltration and methylation
Beibei Lv, Fenna Zhang, Xinyi Zhang, Ziyi Wang, Shuai Hao, Na Ye, Na He
Journal of Molecular Histology.2025;[Epub] CrossRef
NUF2 regulated the progression of hepatocellular carcinoma through modulating the PI3K/AKT pathway via stabilizing ERBB3
Yiwei Liu, Yuming Wang, Jifei Wang, Wangjie Jiang, Yananlan Chen, Jijun Shan, Xiao Li, Xiaofeng Wu
Translational Oncology.2024; 44: 101933. CrossRef
Deciphering the latent biomarkers in HBV and HDV- associated HepatoCellular carcinoma – An integrated bioinformatics analysis
Nandan Dixit, Maulikkumar Patel, Harsha Motwani, Saumya K. Patel, Rakesh M. Rawal, Hiteshkumar A. Solanki
Human Gene.2024; 40: 201287. CrossRef
Expression of Nuclear Division Cycle 80 Complex Genes in Ovarian Cancer and Correlation with the Clinicopathological Features and Survival Outcomes
Mai A. Nasser, Basel Refky, Hanaa M. Abdeen, Mustafa Neamatallah, Hoda Ahmed Nada, Mahmoud Adel Abd Elghaffar
Indian Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Targeting NUF2 suppresses gastric cancer progression through G2/M phase arrest and apoptosis induction
Bo Long, Huinian Zhou, Lixia Xiao, Xiangyan Jiang, Jian Li, Zhijian Ma, Na He, Wei Xin, Boya Zhang, Xiaoqin Zhu, Zeyuan Yu, Zuoyi Jiao
Chinese Medical Journal.2024; 137(20): 2437. CrossRef
Maintenance of magnesium homeostasis by NUF2 promotes protein synthesis and anaplastic thyroid cancer progression
Lisha Bao, Yingying Gong, Yulu Che, Ying Li, Tong Xu, Jinming Chen, Shanshan Wang, Zhuo Tan, Ping Huang, Zongfu Pan, Minghua Ge
Cell Death & Disease.2024;[Epub] CrossRef
NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer
Meng Ren, Hongyu Zhao, Yan Gao, Qi Chen, Xiaoting Zhao, Wentao Yue
Journal of Ovarian Research.2023;[Epub] CrossRef
FOXM1 promotes neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor progression in a NUF2-dependent manner
Rehanguli Aimaier, Man-Hon Chung, Yihui Gu, Qingxiong Yu, Chengjiang Wei, Haibo Li, Zizhen Guo, Manmei Long, Yuehua Li, Wei Wang, Qingfeng Li, Zhichao Wang
Cancer Gene Therapy.2023; 30(10): 1390. CrossRef
Construction of a Prognosis-Related Gene Signature by Weighted Gene Coexpression Network Analysis in Ewing Sarcoma
Runhan Zhao, Chuang Xiong, Chao Zhang, Lin Wang, Hao Liang, Xiaoji Luo, Po-Hsiang Tsui
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
FOXM1‐mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway
Liang Guo, Zhangyi Wu
Neuropathology.2022; 42(5): 430. CrossRef
NUF2 Expression Promotes Lung Adenocarcinoma Progression and Is Associated With Poor Prognosis
Feng Jiang, Xiaolu Huang, Xiang Yang, Huixin Zhou, Yumin Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma
Zhaoshui Li, Zaiqi Ma, Hong Xue, Ruxin Shen, Kun Qin, Yu Zhang, Xin Zheng, Guodong Zhang
Frontiers in Genetics.2022;[Epub] CrossRef
Evaluating the Expression and Prognostic Value of Genes Encoding Microtubule-Associated Proteins in Lung Cancer
Natsaranyatron Singharajkomron, Varalee Yodsurang, Suthasinee Seephan, Sakkarin Kungsukool, Supinda Petchjorm, Nara Maneeganjanasing, Warunyu Promboon, Wadsana Dangwilailuck, Varisa Pongrakhananon
International Journal of Molecular Sciences.2022; 23(23): 14724. CrossRef
NUF2 overexpression contributes to epithelial ovarian cancer progression via ERBB3-mediated PI3K-AKT and MAPK signaling axes
Ruobing Leng, Yunfang Meng, Xiaomei Sun, Yingzi Zhao
Frontiers in Oncology.2022;[Epub] CrossRef
Role of chromosome 1q copy number variation in hepatocellular carcinoma
Nathan R Jacobs, Pamela A Norton
World Journal of Hepatology.2021; 13(6): 662. CrossRef

8,082 View
246 Download
15 Web of Science
16 Crossref

Association of Body Composition with Long-Term Survival in Non-metastatic Rectal Cancer Patients: Jin Soo Han, Hyoseon Ryu, In Ja Park, Kyung Won Kim, Yongbin Shin, Sun Ok Kim, Seok-Byung Lim, Chan Wook Kim, Yong Sik Yoon, Jong Lyul Lee, Chang Sik Yu, Jin Cheon Kim; Cancer Res Treat. 2020;52(2):563-572. Published online December 3, 2019; DOI: https://doi.org/10.4143/crt.2019.249

Abstract PDF PubReader ePub

Purpose
We evaluated the association of body composition with long-term oncologic outcomes in non-metastatic rectal cancer patients.
Methods
We included 1,384 patients with stage(y)0-III rectal cancer treated at Asan Medical Center between January 2005 and December 2012. Body composition at diagnosis was measured using abdomino-pelvic computed tomography (CT). Sarcopenia, visceral obesity (VO), and sarcopenic obesity (SO) were defined using CT measured parameters such as skeletal muscle index (total abdominal muscle area, TAMA), visceral fat area (VFA), and VFA/TAMA. Inflammatory status was defined as a neutrophil-lymphocyte ratio of ≥3. Obesity was categorized by body mass index (≥ 25 kg/m²).
Results
Among the 1,384 patients, 944 (68.2%) had sarcopenia and 307 (22.2%) had SO. The 5-year overall survival (OS) rate was significantly lower in sarcopenic patients (no sarcopenia vs. sarcopenia; 84% vs. 78%, p=0.003) but the 5-year recurrence-free survival (RFS) rate was not different (77.3% vs. 77.9% p=0.957). Patients with SO showed lower 5-year OS (79.1% vs. 75.5% p=0.02) but no difference in 5-year RFS (p=0.957). Sarcopenia, SO, VO, and obesity were not associated with RFS. However, obesity, SO, age, sex, inflammatory status, and tumor stage were confirmed as independent factors associated with OS on multivariate analysis. In subgroup analysis, association of SO with OS was more prominent in patients with (y)p stage 0-2 and no inflammatory status.
Conclusion
The presence of SO and a low body mass index at diagnosis are negatively associated with OS in non-metastatic rectal cancer patients.

Citations

Citations to this article as recorded by

Prognostic Impact of Sarcopenic Obesity on Postoperative Outcomes in Colorectal Cancer Patients Undergoing Surgery: A Systematic Review and Meta-Analysis
Tuba Nur Yıldız Kopuz, Hanifi Furkan Yıldız, Sadettin Er, Mehmet Fisunoğlu
Nutrition and Cancer.2025; 77(3): 360. CrossRef
Effect of sarcopenic obesity on treatment results in patients with malignant tumors of the gastrointestinal tract: systematic review
T. S. Boldyreva, V. K. Lyadov
Supportive Therapy in Oncology.2025; 1(3): 26. CrossRef
Radiological Assessment of Sarcopenia and Its Clinical Impact in Patients with Hepatobiliary, Pancreatic, and Gastrointestinal Diseases: A Comprehensive Review
Shameema Farook, Saumya Soni, Arpit Shantagiri, Pankaj Gupta, Anindita Sinha, Mahesh Prakash
Journal of Gastrointestinal and Abdominal Radiology.2024; 07(01): 027. CrossRef
Landscape and research trends of sarcopenic obesity research: A bibliometric analysis
Huiyu Tang, Rongna Lian, Runjie Li, Jiaojiao Jiang, Ming Yang
Heliyon.2024; 10(2): e24696. CrossRef
Predictive role of preoperative sarcopenia for long-term survival in rectal cancer patients: A meta-analysis
Qiutong Su, Jia Shen, Zubing Mei
PLOS ONE.2024; 19(5): e0303494. CrossRef
Sarcopenic obesity in cancer
Mihaela Jurdana, Maja Cemazar
Radiology and Oncology.2024; 58(1): 1. CrossRef
Negative impact of sarcopenia on survival in elderly patients with colorectal cancer receiving surgery: A propensity‑score matched analysis
Takeshi Nishikawa, Tetsuro Taira, Nao Kakizawa, Riki Ohno, Toshiya Nagasaki
Oncology Letters.2024;[Epub] CrossRef
Impact of body composition parameters on radiation therapy compliance in locally advanced rectal cancer: A retrospective observational analysis
Giuditta Chiloiro, Marco Cintoni, Marta Palombaro, Angela Romano, Sara Reina, Gabriele Pulcini, Barbara Corvari, Silvia Di Franco, Elisa Meldolesi, Gabriele Egidi, Futura Grassi, Pauline Raoul, Emanuele Rinninella, Antonio Gasbarrini, Maria Cristina Mele,
Clinical and Translational Radiation Oncology.2024; 47: 100789. CrossRef
Post‐diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis
Nerea Becerra‐Tomás, Georgios Markozannes, Margarita Cariolou, Katia Balducci, Rita Vieira, Sonia Kiss, Dagfinn Aune, Darren C. Greenwood, Laure Dossus, Ellen Copson, Andrew G. Renehan, Martijn Bours, Wendy Demark‐Wahnefried, Melissa M. Hudson, Anne M. Ma
International Journal of Cancer.2024; 155(3): 400. CrossRef
Sarcopenia diagnosis in patients with colorectal cancer: a review of computed tomography-based assessments and emerging ways to enhance practicality
Hye Jung Cho, Jeonghyun Kang
Annals of Surgical Treatment and Research.2024; 106(6): 305. CrossRef
Serum tumor marker and CT body composition scoring system predicts outcomes in colorectal cancer surgical patients
Mingming Song, Zhihao Liu, Feihong Wu, Tong Nie, Yixin Heng, Jiaxin Xu, Ning Huang, Xiaoyu Wu, Yinghao Cao, Gang Hu
European Radiology.2024; 34(12): 7596. CrossRef
Computed tomography-measured body composition can predict long-term outcomes for stage I-III colorectal cancer patients
Han Zhou, Lei Tian, Yiting Wu, Sibin Liu
Frontiers in Oncology.2024;[Epub] CrossRef
Prognostic significance of serum creatinine and sarcopenia for 5-year overall survival in patients with colorectal cancer in Korea: a comparative study
Jiahn Choi, Hye Sun Lee, Jeonghyun Kang
Annals of Clinical Nutrition and Metabolism.2024; 16(2): 66. CrossRef
Age as a modifier of the effects of sarcopenia on survival among colon cancer patients after surgery
Wen‐Li Lin, Li‐Min Wu, Wen‐Tsung Huang, How‐Ran Guo, Jyh‐Jou Chen
Journal of Surgical Oncology.2023; 128(7): 1121. CrossRef
Associations of muscle and adipose tissue parameters with long-term outcomes in middle and low rectal cancer: a retrospective cohort study
Jiyang Liu, Xiongfeng Yu, Xueqing Huang, Qingquan Lai, Jieyun Chen
Cancer Imaging.2023;[Epub] CrossRef
Associations of Total Body Fat Mass and Skeletal Muscle Index with All-Cause and Cancer-Specific Mortality in Cancer Survivors
Livingstone Aduse-Poku, Shama D. Karanth, Meghann Wheeler, Danting Yang, Caretia Washington, Young-Rock Hong, Todd M. Manini, Jesus C. Fabregas, Ting-Yuan David Cheng, Dejana Braithwaite
Cancers.2023; 15(4): 1081. CrossRef
Prognostic effect of sarcopenia in patients undergoing laparoscopic rectal cancer resection
Giuseppe Portale, Matteo Zuin, Ylenia Camilla Spolverato, Patrizia Bartolotta, Dario Gregori, Carlo Rettore, Luca Cancian, Alberto Morabito, Teodoro Sava, Valentino Fiscon
ANZ Journal of Surgery.2023; 93(6): 1631. CrossRef
Nomogram for predicting the overall survival of underweight patients with colorectal cancer: a clinical study
Jun Woo Bong, Younghyun Na, Yeonuk Ju, Chinock Cheong, Sanghee Kang, Sun Il Lee, Byung Wook Min
BMC Gastroenterology.2023;[Epub] CrossRef
Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: systematic review and meta-analysis
Giuseppe Portale, Patrizia Bartolotta, Danila Azzolina, Dario Gregori, Valentino Fiscon
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
The effects of muscle mass and quality on mortality of patients with acute kidney injury requiring continuous renal replacement therapy
Jiyun Jung, Jangwook Lee, Jeong-Hoon Lim, Yong Chul Kim, Tae Hyun Ban, Woo Yeong Park, Kyeong Min Kim, Kipyo Kim, Sung Woo Lee, Sung Joon Shin, Seung Seok Han, Dong Ki Kim, Yousun Ko, Kyung Won Kim, Hyosang Kim, Jae Yoon Park
Scientific Reports.2023;[Epub] CrossRef
Sarcopenic Obesity Is a Risk Factor for Worse Oncological Long-Term Outcome in Locally Advanced Rectal Cancer Patients: A Retrospective Single-Center Cohort Study
Peter Tschann, Markus P. Weigl, Patrick Clemens, Philipp Szeverinski, Christian Attenberger, Matthias Kowatsch, Tarkan Jäger, Klaus Emmanuel, Thomas Brock, Ingmar Königsrainer
Nutrients.2023; 15(11): 2632. CrossRef
Association between Computed Tomography-Determined Loss of Muscle Mass and Impaired Three-Month Survival in Frail Older Adults with Cancer
Antti Tolonen, Hanna Kerminen, Kaisa Lehtomäki, Heini Huhtala, Maarit Bärlund, Pia Österlund, Otso Arponen
Cancers.2023; 15(13): 3398. CrossRef
Diagnosis and prevalence of sarcopenic obesity in patients with colorectal cancer: A scoping review
Yoko Saino, Fumiya Kawase, Ayano Nagano, Junko Ueshima, Haruko Kobayashi, Kenta Murotani, Tatsuro Inoue, Shinsuke Nagami, Mizue Suzuki, Keisuke Maeda
Clinical Nutrition.2023; 42(9): 1595. CrossRef
Sarcopenia as a prognostic indicator in colorectal cancer: an updated meta-analysis
Jie He, Wei Luo, Yuanyuan Huang, Lingmeng Song, Yang Mei
Frontiers in Oncology.2023;[Epub] CrossRef
Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma
Oliver Guido Verhoek, Lisa Jungblut, Olivia Lauk, Christian Blüthgen, Isabelle Opitz, Thomas Frauenfelder, Katharina Martini
Diagnostics.2022; 12(1): 99. CrossRef
Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy
Alessandro Giani, Simone Famularo, Alessandro Fogliati, Luca Riva, Nicolò Tamini, Davide Ippolito, Luca Nespoli, Marco Braga, Luca Gianotti
World Journal of Surgical Oncology.2022;[Epub] CrossRef
Value-added Opportunistic CT Screening: State of the Art
Perry J. Pickhardt
Radiology.2022; 303(2): 241. CrossRef
Sarcopenic obesity: What about in the cancer setting?
Gianluca Gortan Cappellari, Caterina Brasacchio, Daniela Laudisio, Carla Lubrano, Francesca Pivari, Luigi Barrea, Giovanna Muscogiuri, Silvia Savastano, Annamaria Colao
Nutrition.2022; 98: 111624. CrossRef
CT-Derived Body Composition Assessment as a Prognostic Tool in Oncologic Patients: From Opportunistic Research to Artificial Intelligence–Based Clinical Implementation
David D. B. Bates, Perry J. Pickhardt
American Journal of Roentgenology.2022; 219(4): 671. CrossRef
Prevalence and prognostic value of sarcopenic obesity in patients with cancer: A systematic review and meta-analysis
Qianqian Gao, Kaiyan Hu, Jing Gao, Yi Shang, Fan Mei, Li Zhao, Fei Chen, Bin Ma
Nutrition.2022; 101: 111704. CrossRef
Prognostic value of sarcopenia in patients with rectal cancer: A meta-analysis
Yueli Zhu, Xiaoming Guo, Qin Zhang, Yunmei Yang, Zubing Mei
PLOS ONE.2022; 17(6): e0270332. CrossRef
A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer
Constantinos Simillis, Beth Taylor, Ayesha Ahmad, Nikhil Lal, Thalia Afxentiou, Michael P. Powar, Elizabeth C. Smyth, Nicola S. Fearnhead, James Wheeler, Richard J. Davies
European Journal of Cancer.2022; 172: 237. CrossRef
Sarcobesity Index Predicts Poor Disease-Specific Survival After Resection for Colorectal Cancer
Cristian Conti, Giulia Turri, Gabriele Gecchele, Simone Conci, Giulia A. Zamboni, Andrea Ruzzenente, Alfredo Guglielmi, Corrado Pedrazzani
Journal of Surgical Research.2022; 279: 398. CrossRef
Sarcopenic obesity and therapeutic outcomes in gastrointestinal surgical oncology: A meta-analysis
Peiyu Wang, Shaodong Wang, Yi Ma, Haoran Li, Zheng Liu, Guihu Lin, Xiao Li, Fan Yang, Mantang Qiu
Frontiers in Nutrition.2022;[Epub] CrossRef
Adiposity and cancer survival: a systematic review and meta-analysis
En Cheng, Jocelyn Kirley, Elizabeth M. Cespedes Feliciano, Bette J. Caan
Cancer Causes & Control.2022; 33(10): 1219. CrossRef
Obesity may not be related to pathologic response in locally advanced rectal cancer following neoadjuvant chemoradiotherapy
Quoc Riccardo Bao, Filippo Crimì, Giovanni Valotto, Valentina Chiminazzo, Francesca Bergamo, Alessandra Anna Prete, Sara Galuppo, Badr El Khouzai, Emilio Quaia, Salvatore Pucciarelli, Emanuele Damiano Luca Urso
Frontiers in Oncology.2022;[Epub] CrossRef
Lifestyle interventions after colorectal cancer surgery using a mobile digital device: A study protocol for a randomized controlled trial
Young Il Kim, In Ja Park, Chan Wook Kim, Yong Sik Yoon, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim, Yura Lee, Harin Kim, Seockhoon Chung, Chang-Min Choi, Hui Jeong Lee, Kyung Won Kim, Yousun Ko, Sung-Cheol Yun, Min-Woo Jo, Jong Won Lee
Medicine.2022; 101(41): e31264. CrossRef
Serial Changes in Body Composition and the Association with Disease Activity during Treatment in Patients with Crohn’s Disease
Ji Young Lee, Kyung Won Kim, Yousun Ko, Chi Hyuk Oh, Bo Hyun Kim, Seong Jin Park, Myung-Won You
Diagnostics.2022; 12(11): 2804. CrossRef
Sarcopenia as a Prognostic Marker in Elderly Head and Neck Squamous Cell Carcinoma Patients Undergoing (Chemo-)Radiation
Erik Haehl, Luisa Alvino, Alexander Rühle, Jiadai Zou, Alexander Fabian, Anca-Ligia Grosu, Nils H. Nicolay
Cancers.2022; 14(22): 5536. CrossRef
Marked loss of adipose tissue during neoadjuvant therapy as a predictor for poor prognosis in patients with gastric cancer: A retrospective cohort study
Yingjing Zhang, Zijian Li, Lin Jiang, Zhigang Xue, Zhiqiang Ma, Weiming Kang, Xin Ye, Yuqin Liu, Zhengyu Jin, Jianchun Yu
Journal of Human Nutrition and Dietetics.2021; 34(3): 585. CrossRef
Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer: a systematic review and meta-analysis
Mario Trejo-Avila, Katya Bozada-Gutiérrez, Carlos Valenzuela-Salazar, Jesús Herrera-Esquivel, Mucio Moreno-Portillo
International Journal of Colorectal Disease.2021; 36(6): 1077. CrossRef
Prognostic and predictive value of neutrophil-to-lymphocyte ratio after curative rectal cancer resection: A systematic review and meta-analysis
Hytham K.S. Hamid, George N. Davis, Mario Trejo-Avila, Patrick O. Igwe, Andrés Garcia-Marín
Surgical Oncology.2021; 37: 101556. CrossRef
The Role of Sarcopenic Obesity in Cancer and Cardiovascular Disease: A Synthesis of the Evidence on Pathophysiological Aspects and Clinical Implications
Erika Aparecida Silveira, Rômulo Roosevelt da Silva Filho, Maria Claudia Bernardes Spexoto, Fahimeh Haghighatdoost, Nizal Sarrafzadegan, Cesar de Oliveira
International Journal of Molecular Sciences.2021; 22(9): 4339. CrossRef
Influence of Postoperative Changes in Sarcopenia on Long-Term Survival in Non-Metastatic Colorectal Cancer Patients
Chungyeop Lee, In-Ja Park, Kyung-Won Kim, Yongbin Shin, Seok-Byung Lim, Chan-Wook Kim, Yong-Sik Yoon, Jong-Lyul Lee, Chang-Sik Yu, Jin-Cheon Kim
Cancers.2021; 13(10): 2410. CrossRef
Preoperative computed tomography-assessed sarcopenia as a predictor of complications and long-term prognosis in patients with colorectal cancer: a systematic review and meta-analysis
Hailun Xie, Lishuang Wei, Mingxiang Liu, Guanghui Yuan, Shuangyi Tang, Jialiang Gan
Langenbeck's Archives of Surgery.2021; 406(6): 1775. CrossRef
Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review
Antti Tolonen, Tomppa Pakarinen, Antti Sassi, Jere Kyttä, William Cancino, Irina Rinta-Kiikka, Said Pertuz, Otso Arponen
European Journal of Radiology.2021; 145: 109943. CrossRef
Skeletal muscle gauge as a prognostic factor in patients with colorectal cancer
In Kyu Park, Song Soo Yang, Eric Chung, Eun‐Suk Cho, Hye Sun Lee, Su‐Jin Shin, Yeong Cheol Im, Eun Jung Park, Seung Hyuk Baik, Kang Young Lee, Jeonghyun Kang
Cancer Medicine.2021; 10(23): 8451. CrossRef
Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review
Xiao-Ming Zhang, Qing-Li Dou, Yingchun Zeng, Yunzhi Yang, Andy S. K. Cheng, Wen-Wu Zhang
BMC Cancer.2020;[Epub] CrossRef
Sarcopenia Is Associated With Hematologic Toxicity During Chemoradiotherapy in Patients With Anal Carcinoma
Daniel Martin, Jens von der Grün, Claus Rödel, Emmanouil Fokas
Frontiers in Oncology.2020;[Epub] CrossRef

10,019 View
325 Download
47 Web of Science
49 Crossref

Prognostic Value of Post-diagnosis Health-Related Quality of Life for Overall Survival in Breast Cancer: Findings from a 10-Year Prospective Cohort in Korea: Tran Thi Xuan Mai, Jin Hyuk Choi, Myung Kyung Lee, Yoon Jung Chang, So-Youn Jung, Hyunsoon Cho, Eun Sook Lee; Cancer Res Treat. 2019;51(4):1600-1611. Published online April 12, 2019; DOI: https://doi.org/10.4143/crt.2018.426

Abstract PDF PubReader ePub

Purpose
We aimed to evaluate health-related quality of life (HRQOL) at 1-year post-diagnosis in breast cancer (BC) patients and its association with overall survival using data from the National Cancer Center Hospital.
Materials and Methods
Data of a BC cohort were first obtained between 2004 and 2006 and followed up. HRQOL was assessed using EORTC QLQ-C30 and BC specific module QLQ-BR23 few days after diagnosis and 1 year after that. We examined and compared the difference in the two HRQOL scores measured for each patient by the patient’s current survival status. The Cox proportional hazards model was fitted to evaluate the impact of HRQOL on survival, with adjustment for baseline HRQOL and other factors.
Results
Of 299 enrolled patients, 206 responded at 1-year post-diagnosis (80.6%) and were followed up for 11.6 years on average. At 1-year post-diagnosis, survivors had better HRQOL scores than those who died, although their health status was similar at baseline. Survivors reported significant increase 1 year after diagnosis in global health status and emotional scales. Between the groups, functional scales such as physical, role, and emotional were significantly different. Functional scales, including physical (adjusted hazard ratio [aHR], 0.70), role (aHR, 0.68), emotional (aHR, 0.72), and symptom scales, including fatigue (aHR, 1.34), dyspnea (aHR, 1.29), appetite loss (aHR, 1.24) were significantly associated with overall survival. Patients who were less worried about future health had favorable survival (aHR, 0.83).
Conclusion
Besides treatment-related symptoms, non-medical aspects at 1-year post-diagnosis, including functional well-being and future perspective, are predictive of long-term survival. Intervention to enhance physical, role, and emotional support for women soon after their BC diagnosis might help to improve disease survival outcomes afterwards.

Citations

Citations to this article as recorded by

Health-related quality of life in long-term early-stage breast cancer survivors compared to general population in Korea
Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Na Yeon Kim, Sungkeun Shim, Ho Young Kim, Danbee Kang, Juhee Cho, Eunsook Lee, Yoonjung Chang, Hyunsoon Cho
Journal of Cancer Survivorship.2025; 19(2): 487. CrossRef
Lower Adherence to Lifestyle Recommendations of the World Cancer Research Fund/American Institute for Cancer Research (2018) Is Associated with Decreased Overall 10-Year Survival in Women with Breast Cancer
Jaqueline Schroeder de Souza, Luiza Kuhnen Reitz, Cândice Laís Knöner Copetti, Yara Maria Franco Moreno, Francilene Gracieli Kunradi Vieira, Patricia Faria Di Pietro
Nutrients.2025; 17(6): 1001. CrossRef
Long-term trajectory of postoperative health-related quality of life in young breast cancer patients: a 15-year follow-up study
Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Juhee Cho, Eunsook Lee, Yoon Jung Chang, Hyunsoon Cho
Journal of Cancer Survivorship.2023; 17(5): 1416. CrossRef
Associations between health-related fitness and quality of life in newly diagnosed breast cancer patients
Kerry S. Courneya, Ki-Yong An, Fernanda Z. Arthuso, Gordon J. Bell, Andria R. Morielli, Jessica McNeil, Qinggang Wang, Spencer J. Allen, Stephanie M. Ntoukas, Margaret L. McNeely, Jeff K. Vallance, S. Nicole Culos-Reed, Karen Kopciuk, Lin Yang, Charles E.
Breast Cancer Research and Treatment.2023; 199(3): 533. CrossRef
Quality of life and cost-effectiveness of different breast cancer surgery procedures: a Markov decision tree-based approach in the framework of Predictive, Preventive, and Personalized Medicine
Hon-Yi Shi, Chiu-Hui Li, Yen-Chen Chen, Chong-Chi Chiu, Hao-Hsien Lee, Ming-Feng Hou
EPMA Journal.2023; 14(3): 457. CrossRef
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-
Clinical and Translational Oncology.2023; 25(12): 3492. CrossRef
Illness Perception and Quality of Life in Patients with Breast Cancer
Edyta Ośmiałowska, Jakub Staś, Mariusz Chabowski, Beata Jankowska-Polańska
Cancers.2022; 14(5): 1214. CrossRef
Psychometric Evaluation of the Korean Version of the Functional Assessment of Chronic Illness Therapy-Fatigue
Won-Gyeom LEE, Hee-Ju KIM
Journal of Nursing Research.2022;[Epub] CrossRef
Digital and Interactive Health Interventions Minimize the Physical and Psychological Impact of Breast Cancer, Increasing Women’s Quality of Life: A Systematic Review and Meta-Analysis
Esteban Obrero-Gaitán, Irene Cortés-Pérez, Tania Calet-Fernández, Héctor García-López, María del Carmen López Ruiz, María Catalina Osuna-Pérez
Cancers.2022; 14(17): 4133. CrossRef
Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors
Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Na Yeon Kim, Sungkeun Shim, Ho Young Kim, Danbee Kang, Juhee Cho, Eunsook Lee, Yoon Jung Chang, Hyunsoon Cho
Cancer Research and Treatment.2022; 54(4): 1065. CrossRef
Cancer-related Fatigue in Breast Cancer Survivors: A Review
Ana Ruiz-Casado, Alejandro Álvarez-Bustos, Cristina G. de Pedro, Marta Méndez-Otero, María Romero-Elías
Clinical Breast Cancer.2021; 21(1): 10. CrossRef
Cancer outcomes research—a European challenge: measures of the cancer burden
Mette Kalager, Hans‐Olov Adami, Pernilla Lagergren, Karen Steindorf, Paul W. Dickman
Molecular Oncology.2021; 15(12): 3225. CrossRef
Weight Change in Post-Menopausal Women with Breast Cancer during Chemotherapy—Perspectives on Nutrition, Activity and Bone Metabolism: An Interim Analysis of a 5-Year Prospective Cohort
Kristian Buch-Larsen, Trine Lund-Jacobsen, Michael Andersson, Peter Schwarz
Nutrients.2021; 13(8): 2902. CrossRef
Unmet supportive care needs of survival patients with breast cancer in different cancer stages and treatment phases
Ying-Hsiang Chou, Vivian Chia-Rong Hsieh, XianXiu Chen, Ting-Yi Huang, Shwn-Huey Shieh
Taiwanese Journal of Obstetrics and Gynecology.2020; 59(2): 231. CrossRef
Quality of life in advanced cancer patients
Satvik Khaddar
Cancer Research, Statistics, and Treatment.2020; 3(1): 117. CrossRef

8,608 View
189 Download
14 Web of Science
15 Crossref

Circulating Low Absolute CD4⁺ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy: Ya-Ping Zhang, Run Zhang, Hua-Yuan Zhu, Li Wang, Yu-Jie Wu, Jin-Hua Liang, Wen-Yu Shi, Hong Liu, Wei Xu, Jian-Yong Li; Cancer Res Treat. 2019;51(1):368-377. Published online May 14, 2018; DOI: https://doi.org/10.4143/crt.2018.010

Abstract PDF PubReader ePub

Purpose
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare subtype of non-Hodgkin lymphoma, and asparaginase-based regimens are the best first-line treatments. Data on the role of specific circulating lymphocyte subsets in the progression of ENKTL are limited. The aim of this study was to investigate the clinical correlation and distribution of circulating absolute CD4+ T-cell counts (ACD4Cs) in ENKTL.
Materials and Methods
We retrospectively searched medical records for 70 newly diagnosed ENKTL patients treated with pegaspargase-based regimens. Comparison of ACD4Cs as a continuous parameter in different groups was calculated. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS).
Results
Stage III/IV, B symptoms, elevated lactate dehydrogenase, monocytopenia, high-intermediate and high risk International Prognostic Index (IPI) and Korean Prognostic Index (KPI), high risk Prognostic Index of Natural Killer Lymphoma (PINK), and lower lymphocytes were significantly associated with low ACD4C at diagnosis. With a median follow-up time of 32 months, patients who had an ACD4C < 0.30×109/L had a worse OS. Median OS was 11 months and median PFS was 5 months in the low ACD4C cohort. There were significant differences in both OS and PFS between the two cohorts. Moreover, multivariate Cox analysis identified ACD4Cs as an independent predictor for OS and PFS.
Conclusion
Low ACD4Cs were associated with poorer survival and could act as a negative predictor for ENKTL patients treated with asparaginase-based regimens.

Citations

Citations to this article as recorded by

Prognostic Value of Peripheral Blood Lymphocyte Subsets in Children and Adolescents With High‐Grade Mature B‐Cell Non‐Hodgkin Lymphoma: A Real‐World Outcomes Study
Chenggong Zeng, Zhiqing Wei, Junting Huang, Jia Zhu, Feifei Sun, Juan Wang, Suying Lu, Yizhuo Zhang, Xiaofei Sun, Zijun Zhen
Pediatric Blood & Cancer.2025;[Epub] CrossRef
Low levels of CD3 + and CD8 + T cells in peripheral blood can predict poor efficacy of first-line chemotherapy in patients with angioimmunoblastic T cell lymphoma
Yanfei Liu, Weiwei Song, Yuqin Song, Jun Zhu, Yan Xie
Annals of Hematology.2025; 104(3): 1705. CrossRef
Identification and validation of ubiquitin-proteasome system related genes as a prognostic signature for papillary renal cell carcinoma
Xin Zhang, Xinli Liu, Renhua Xiong, Han-Xiang An
Aging.2022;[Epub] CrossRef
An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
Yaxiao Lu, Jingwei Yu, Wenchen Gong, Liping Su, Xiuhua Sun, Ou Bai, Hui Zhou, Xue Guan, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang
Frontiers in Oncology.2021;[Epub] CrossRef
Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
Jason Yongsheng Chan, Jing Quan Lim, Choon Kiat Ong
Life.2021; 11(8): 838. CrossRef
The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma
Shengnan Zhang, Mengjuan Li, Fangfang Yuan, Lin Chen, Ruihua Mi, Xudong Wei, Yongping Song, Qingsong Yin
Cancer Cell International.2019;[Epub] CrossRef
It’s all about the CD3+ T-cells: how circulating immune cell subset analyses can predict early relapse in Hodgkin lymphoma
Jonathan Moreira, Leonidas C. Platanias, Kehinde U. A. Adekola
Leukemia & Lymphoma.2019; 60(10): 2345. CrossRef
The combined prognostic value of pretreatment neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in stage IE/IIE extranodal natural killer/T-cell lymphoma
Xiaoying Quan
Oncology and Translational Medicine.2019; : 137. CrossRef

8,563 View
217 Download
9 Web of Science
8 Crossref

Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function: Yeonjung Ha, Daejung Kim, Seungbong Han, Young Eun Chon, Yun Bin Lee, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang; Cancer Res Treat. 2018;50(3):843-851. Published online September 4, 2017; DOI: https://doi.org/10.4143/crt.2017.232

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to demonstrate the prognostic significance of changes in body composition in patients with newly diagnosed hepatocellular carcinoma (HCC).
Materials and Methods
Patients (n=178) newly diagnosed with HCC participated in the study between 2007 and 2012. Areas of skeletal muscle and abdominal fat were directly measured using a three-dimensional workstation. Cox proportional-hazards modes were used to estimate the effect of baseline variables on overall survival. The inverse probability of treatmentweighting (IPTW) method was used to minimize confounding bias.
Results
Cutoff values for sarcopenia, obtained from receiver-operating characteristic curves, were defined as skeletal muscle index at the third lumbar vertebra of ≤ 45.8 cm/m² for males and ≤ 43.0 cm/m² for females. Sarcopenia patients were older, more likely to be female, and had lower body mass index. Univariable analysis showed that the presence of sarcopenia and visceral to subcutaneous fat area ratio (VSR) were significantly associatedwith prognosis. The multivariable analyses revealed that VSR was predictive of overall survival. However, in the multivariable Cox model adjusted by IPTW, sarcopenia, not VSR, were associated with overall survival.
Conclusion
The presence of sarcopenia at HCC diagnosis is independently associated with survival.

Citations

Citations to this article as recorded by

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
Hepatology International.2025; 19(2): 261. CrossRef
Sarcopenia Affects Liver Regeneration and Long-Term Survival Rate After Living-Donor Liver Transplantation in Patients With Hepatocellular Carcinoma
Mei-Yun Wu, Cheng-Hsi Yeh, Chien-Chang Liao, Chao-Long Chen, Chih-Chi Wang, Chih-Che Lin, Wan- Ching Chang, Yu-Fan Cheng, Hsin-You Ou
Transplantation Proceedings.2024; 56(3): 573. CrossRef
Effect of Sarcopenia on the Prognosis of Clinical Outcomes in Patients With Hepatocellular Carcinoma After Hepatic Resection
Thanatchawan Polvieng, Sermsak Hongjinda, Anuparp Thienhiran, Pipit Burasakarn, Pusit Fuengfoo
The American Surgeon™.2024; 90(6): 1447. CrossRef
Hepatocellular carcinoma and musculoskeletal system: A narrative literature review
Jelena Jadzic, Danijela Djonic
World Journal of Gastroenterology.2024; 30(15): 2109. CrossRef
Apolipoprotein A-1 downregulation promotes basal-like breast cancer cell proliferation and migration associated with DNA methylation
Cong Wang, Shiliang Chen, Ranran Zhang, Mengqing Chen, Xiaoxiao Yang, Yibo He, Zuifei Shangguan, Qifen Mao, Zhezhong Zhang, Sunke Ying
Oncology Letters.2024;[Epub] CrossRef
Association between visceral obesity and tumor recurrence in hepatocellular carcinoma recipients undergoing liver transplantation
Ji-Hoon Sim, Kyung-Won Kim, YouSun Ko, Young-Jin Moon, Hye-Mee Kwon, In-Gu Jun, Sung-Hoon Kim, Kyoung-Sun Kim, Jun-Gol Song, Gyu-Sam Hwang
International Journal of Obesity.2023; 47(12): 1214. CrossRef
Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis
Yusheng Guo, Yanqiao Ren, Licheng Zhu, Lian Yang, Chuansheng Zheng
Scientific Reports.2023;[Epub] CrossRef
Creatine Supplementation to Improve Sarcopenia in Chronic Liver Disease: Facts and Perspectives
Riccardo Casciola, Laura Leoni, Biagio Cuffari, Maddalena Pecchini, Renata Menozzi, Antonio Colecchia, Federico Ravaioli
Nutrients.2023; 15(4): 863. CrossRef
Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment
Anne-Laure Couderc, Evelyne Liuu, Pascaline Boudou-Rouquette, Johanne Poisson, Maxime Frelaut, Coline Montégut, Soraya Mebarki, Romain Geiss, Zoé ap Thomas, Aurélien Noret, Monica Pierro, Capucine Baldini, Elena Paillaud, Frédéric Pamoukdjian
Nutrients.2023; 15(5): 1193. CrossRef
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
Alexey Surov, Maximilian Thormann, Mattes Hinnerichs, Max Seidensticker, Ricarda Seidensticker, Osman Öcal, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Iren
Hepatology Communications.2023;[Epub] CrossRef
Prevalence of sarcopenia among patients with hepatocellular carcinoma: A systematic review and meta‑analysis
Jiye Liu, Hanyong Luo, Letian Huang, Jiahe Wang
Oncology Letters.2023;[Epub] CrossRef
Adipose distribution patterns as prognostic factors in patients with HCC: A systematic review and meta-analysis
Shuo Shi, Haiyan Yi, Yi Zheng, Yuxuan Zhao, Dexin Yu
European Journal of Radiology.2023; 167: 111025. CrossRef
Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis
Xuanmei Li, Xue Huang, Lifu Lei, Shiwen Tong
Frontiers in Nutrition.2023;[Epub] CrossRef
A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol
Patrik Nasr, Mikael Forsgren, Wile Balkhed, Cecilia Jönsson, Nils Dahlström, Christian Simonsson, Shan Cai, Anna Cederborg, Martin Henriksson, Henrik Stjernman, Martin Rejler, Daniel Sjögren, Gunnar Cedersund, Wolf Bartholomä, Ingvar Rydén, Peter Lundberg
BMC Gastroenterology.2023;[Epub] CrossRef
Sarcopenia as a prognostic indicator of liver cirrhosis
Sung‐Eun Kim, Dong Joon Kim
Journal of Cachexia, Sarcopenia and Muscle.2022; 13(1): 8. CrossRef
Comparison of frailty metrics and the Charlson Comorbidity Index for predicting adverse outcomes in patients undergoing surgery for spine metastases
Andrew M. Hersh, Zach Pennington, Bethany Hung, Jaimin Patel, Earl Goldsborough, Andrew Schilling, James Feghali, Albert Antar, Siddhartha Srivastava, David Botros, Aladine A. Elsamadicy, Sheng-Fu Larry Lo, Daniel M. Sciubba
Journal of Neurosurgery: Spine.2022; 36(5): 849. CrossRef
Sarcopenia of Cirrhosis and the Therapeutic Potential of Transjugular Intrahepatic Portosystemic Shunt Creation
Barry Schlansky, Khashayar Farsad
Digestive Disease Interventions.2022; 06(02): 148. CrossRef
Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions
Abhilash Perisetti, Hemant Goyal, Rachana Yendala, Saurabh Chandan, Benjamin Tharian, Ragesh Babu Thandassery
World Journal of Gastroenterology.2022; 28(4): 432. CrossRef
The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Yasser Fouad, Gamal Esmat, Reda Elwakil, Serag Zakaria, Ayman Yosry, Imam Waked, Maissa El-Razky, Wahid Doss, Magdy El-Serafy, Ebraheem Mostafa, Mahmood Anees, Mohamed A. Sakr, Nadia AbdelAty, Ashraf Omar, Samy Zaki, Amgad Al-zahaby, Hamdy Mahfouz, Maysaa
Saudi Journal of Gastroenterology.2022; 28(1): 3. CrossRef
Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis
Christine March, Jazan Omari, Maximilian Thormann, Maciej Pech, Andreas Wienke, Alexey Surov
Clinical Nutrition ESPEN.2022; 49: 103. CrossRef
Adiposity and cancer survival: a systematic review and meta-analysis
En Cheng, Jocelyn Kirley, Elizabeth M. Cespedes Feliciano, Bette J. Caan
Cancer Causes & Control.2022; 33(10): 1219. CrossRef
Preoperative computed tomography-determined sarcopenia is a reliable prognostic factor in patients with gastric cancer after radical gastrectomy: A sex-specific analysis
Ting Liu, Xiaoping Yi, Jie Ge, Jinwei Zhang, Fengbo Tan, Kun Song, Heli Liu, Mimi Tang
Frontiers in Nutrition.2022;[Epub] CrossRef
The psoas muscle depletion index is related to the degree of cirrhosis and skeletal muscle loss in patients with end-stage liver disease
J.C. Hou, Y.M. Zhang, Z Qiang, L.Y. Zhu, H Zheng, Z.Y. Shen
Acta Gastro Enterologica Belgica.2022; 85(3): 453. CrossRef
Imaging based body composition profiling and outcomes after oncologic liver surgery
Lorenzo Bernardi, Raffaello Roesel, Filippo Vagelli, Pietro Majno-Hurst, Alessandra Cristaudi
Frontiers in Oncology.2022;[Epub] CrossRef
Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis
Chuan Jiang, Yanyan Wang, Wei Fu, Guozhuan Zhang, Xiaoshan Feng, Xing Wang, Fang Wang, Le Zhang, Yang Deng
Frontiers in Nutrition.2022;[Epub] CrossRef
MRI-Derived Sarcopenia Associated with Increased Mortality Following Yttrium-90 Radioembolization of Hepatocellular Carcinoma
Phillip L. Guichet, Bedros Taslakian, Chenyang Zhan, Eric Aaltonen, Sean Farquharson, Ryan Hickey, Cash J. Horn, Jonathan S. Gross
CardioVascular and Interventional Radiology.2021; 44(10): 1561. CrossRef
The prevalence and the impact of sarcopenia in digestive cancers. A systematic review
Carmen Haiducu, Adrian Buzea, Liliana Elena Mirea, Gheorghe Andrei Dan
Romanian Journal of Internal Medicine.2021; 59(4): 328. CrossRef
Impact of body fat distribution and sarcopenia on the overall survival in patients with spinal metastases receiving radiotherapy treatment: a prospective cohort study
B. J. Pielkenrood, P. R. van Urk, J. M. van der Velden, N. Kasperts, J. J. C. Verhoeff, G. H. Bol, H. M. Verkooijen, J. J. Verlaan
Acta Oncologica.2020; 59(3): 291. CrossRef
Visceral Adipose Tissue Radiodensity Is Linked to Prognosis in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy
Maryam Ebadi, Carlos Moctezuma-Velazquez, Judith Meza-Junco, Vickie E. Baracos, Abha R. DunichandHoedl, Sunita Ghosh, Philippe Sarlieve, Richard J. Owen, Norman Kneteman, Aldo J. Montano-Loza
Cancers.2020; 12(2): 356. CrossRef
Review article: prognostic significance of body composition abnormalities in patients with cirrhosis
Maryam Ebadi, Rahima A. Bhanji, Puneeta Tandon, Vera Mazurak, Vickie E. Baracos, Aldo J. Montano‐Loza
Alimentary Pharmacology & Therapeutics.2020; 52(4): 600. CrossRef
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv K. Sarin, Vincent Wai-Sun Wong, Jian-Gao Fan, Takumi Kawaguchi, Sang Hoon Ahn, Ming-Hua Zheng, Gamal Shiha, Yusuf Yilmaz, Rino Gani, Shahinul Alam, Yock Young Dan, Jia-Horng Kao, Saeed Hamid, Ian Homer Cua, Wah-Kheong Chan, Diana Paya
Hepatology International.2020; 14(6): 889. CrossRef
Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma
Sooyeon Oh, Jooho Lee
Clinical and Molecular Hepatology.2020; 26(4): 476. CrossRef
The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?
Felix Hahn, Lukas Müller, Fabian Stöhr, Aline Mähringer‐Kunz, Sebastian Schotten, Christoph Düber, Fabian Bartsch, Hauke Lang, Peter R Galle, Arndt Weinmann, Roman Kloeckner
Liver International.2019; 39(7): 1307. CrossRef
Safety and Prognosis of Transarterial Chemoembolization for Octogenarians with Hepatocellular Carcinoma
Hua-Ming Cheng, Toshihiro Tanaka, Hideyuki Nishiofuku, Yuto Chanoki, Katsutoshi Horiuchi, Tetsuya Masada, Shota Tatsumoto, Takeshi Matsumoto, Nagaaki Marugami, Kimihiko Kichikawa
CardioVascular and Interventional Radiology.2019; 42(10): 1413. CrossRef
Visceral Fat Volume From Standard Preoperative CT is an Independent Predictor of Short-term Survival in Patients Undergoing Surgery for Metastatic Spine Disease
Zach Pennington, Bart Pielkenrood, A. Karim Ahmed, C. Rory Goodwin, Jorrit-Jan Verlaan, Daniel M. Sciubba
Clinical Spine Surgery: A Spine Publication.2019; 32(6): E303. CrossRef
Sarcopenia in cirrhosis: from pathogenesis to interventions
Maryam Ebadi, Rahima A. Bhanji, Vera C. Mazurak, Aldo J. Montano-Loza
Journal of Gastroenterology.2019; 54(10): 845. CrossRef
“Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”
Yan Mardian, Yoshihiko Yano, Neneng Ratnasari, Lina Choridah, Widya Wasityastuti, Nurhuda Hendra Setyawan, Yoshitake Hayashi
BMC Gastroenterology.2019;[Epub] CrossRef
Controversies in Diagnosing Sarcopenia in Cirrhosis—Moving from Research to Clinical Practice
Marie Sinclair
Nutrients.2019; 11(10): 2454. CrossRef
Sarcopenia in cirrhosis: a systematic review
Ovidiu Paul Calapod, Andreea Maria Marin, Laura Carina Tribus, Carmen Fierbinţeanu-Braticevici
Romanian Journal of Orthopaedic Surgery and Traumatology.2019; 2(2): 125. CrossRef
The Adverse Impact of Sarcopenia and Visceral Fat Deposition on the Course of Hepatocellular Carcinoma and the Role of Nutritional Interventions
Adam McCulloch, Hardip Malhi, Amritpal Dhaliwal, Sheldon Cooper, Tahir Shah
European Medical Journal.2018; : 126. CrossRef

10,017 View
351 Download
45 Web of Science
40 Crossref

Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model: Pawel Chrom, Rafal Stec, Lubomir Bodnar, Cezary Szczylik; Cancer Res Treat. 2018;50(1):103-110. Published online March 3, 2017; DOI: https://doi.org/10.4143/crt.2017.033

Abstract PDF Supplementary Material PubReader ePub

Purpose
The study investigated whether a replacement of neutrophil count and platelet count by neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) within the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model would improve its prognostic accuracy.
Materials and Methods
This retrospective analysis included consecutive patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. The IMDC and modified-IMDC models were compared using: concordance index (CI), bias-corrected concordance index (BCCI), calibration plots, the Grønnesby and Borgan test, Bayesian Information Criterion (BIC), generalized R², Integrated Discrimination Improvement (IDI), and continuous Net Reclassification Index (cNRI) for individual risk factors and the three risk groups.
Results
Three hundred and twenty-one patients were eligible for analyses. The modified-IMDC model with NLR value of 3.6 and PLR value of 157 was selected for comparison with the IMDC model. Both models were well calibrated. All other measures favoured the modified-IMDC model over the IMDC model (CI, 0.706 vs. 0.677; BCCI, 0.699 vs. 0.671; BIC, 2,176.2 vs. 2,190.7; generalized R², 0.238 vs. 0.202; IDI, 0.044; cNRI, 0.279 for individual risk factors; and CI, 0.669 vs. 0.641; BCCI, 0.669 vs. 0.641; BIC, 2,183.2 vs. 2,198.1; generalized R², 0.163 vs. 0.123; IDI, 0.045; cNRI, 0.165 for the three risk groups).
Conclusion
Incorporation of NLR and PLR in place of neutrophil count and platelet count improved prognostic accuracy of the IMDC model. These findings require external validation before introducing into clinical practice.

Citations

Citations to this article as recorded by

Correlation of Prognostic Nutritional Index and Systemic Immune-Inflammation Index with the Recurrence and Prognosis in Oral Squamous Cell Carcinoma with the Stage of III/IV
Manjun Ye, Lixia Zhang
International Journal of General Medicine.2024; Volume 17: 2289. CrossRef
Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients
Bruce Li, Swati Sood, Melissa J. Huynh, Nicholas E. Power
JU Open Plus.2024;[Epub] CrossRef
The relationship between complete blood cell count-derived inflammatory biomarkers and benign prostatic hyperplasia in middle-aged and elderly individuals in the United States: Evidence from NHANES 2001–2008
Chengdong Shi, Hongliang Cao, Guoqiang Zeng, Lei Yang, Yuantao Wang, Alaa A. A. Aljabali
PLOS ONE.2024; 19(7): e0306860. CrossRef
Evaluation of prognostic factors for late recurrence in clear cell renal carcinoma: an institutional study
Diana Voskuil-Galoş, Tudor Călinici, Andra Piciu, Adina Nemeş
Frontiers in Oncology.2024;[Epub] CrossRef
Plasma carnitine, choline, γ-butyrobetaine, and trimethylamine-N-oxide, but not zonulin, are reduced in overweight/obese patients with pre/diabetes or impaired glycemia
Alia Snouper, Violet Kasabri, Nailya Bulatova, Maysa Suyagh, Monther Sadder, Khaldoun Shnewer, Ismail Yousef
International Journal of Diabetes in Developing Countries.2023; 43(4): 592. CrossRef
Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
Ella Barkan, Camillo Porta, Simona Rabinovici-Cohen, Valentina Tibollo, Silvana Quaglini, Mimma Rizzo
Frontiers in Oncology.2023;[Epub] CrossRef
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Small Renal Cell Carcinomas after Image-Guided Cryoablation or Radio-Frequency Ablation
Aqua Asif, Vinson Wai-Shun Chan, Filzah Hanis Osman, Jasmine Sze-Ern Koe, Alexander Ng, Oliver Edward Burton, Jon Cartledge, Michael Kimuli, Naveen Vasudev, Christy Ralph, Satinder Jagdev, Selina Bhattarai, Jonathan Smith, James Lenton, Tze Min Wah
Cancers.2023; 15(7): 2187. CrossRef
A meta-analysis of the platelet-lymphocyte ratio: A notable prognostic factor in renal cell carcinoma
Xiao Zhou, Guangcheng Luo
The International Journal of Biological Markers.2022; 37(2): 123. CrossRef
Prognostic Role of Systemic Inflammatory Markers in Patients Undergoing Surgical Resection for Oral Squamous Cell Carcinoma
Uiju Cho, Yeoun-Eun Sung, Min-Sik Kim, Youn-Soo Lee
Biomedicines.2022; 10(6): 1268. CrossRef
Prognostic value of glucose to lymphocyte ratio for patients with renal cell carcinoma undergoing laparoscopic nephrectomy: A multi-institutional, propensity score matching cohort study
Jinliang Ni, Ziye Li, Wei Song, Houliang Zhang, Yidi Wang, Yifan Zhang, Haipeng Zhang, Guangcan Yang, Jun Xie, Keyi Wang, Bo Peng, Weipu Mao
Frontiers in Surgery.2022;[Epub] CrossRef
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Yasser Ged, Alejandro Sanchez, Sujata Patil, Andrea Knezevic, Emily Stein, Stacey Petruzella, Kate Weiss, Cihan Duzgol, Joshua Chaim, Oguz Akin, Marina Mourtzakis, Michael T. Paris, Jessica Scott, Fengshen Kuo, Ritesh Kotecha, A. Ari Hakimi, Chung-Han Lee
Clinical Cancer Research.2022; 28(23): 5180. CrossRef
Exploratory Analysis of the Platelet-to-Lymphocyte Ratio Prognostic Value in the Adjuvant Renal Cell Cancer Setting
Anup Patel, Alain Ravaud, Robert J Motzer, Allan J Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, Daniel J George
Future Oncology.2021; 17(4): 403. CrossRef
Preoperative anaemia and thrombocytosis predict adverse prognosis in non‐metastatic renal cell carcinoma with tumour thrombus
Ruotao Xiao, Chuxiao Xu, Wei He, Lei Liu, Hongxian Zhang, Cheng Liu, Lulin Ma
BMC Urology.2021;[Epub] CrossRef
Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma According to Risk Factors: The STAR-TOR Registry
Arne Strauss, Marianne Schmid, Michael Rink, Michael Moran, Stephan Bernhardt, Marcus Hubbe, Lothar Bergmann, Katrin Schlack, Martin Boegemann
Future Oncology.2021; 17(18): 2325. CrossRef
Systemic Inflammation Response Index is an Independent Prognostic Indicator for Patients with Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy: A Multi-Institutional Cohort Study
Weipu Mao, Si Sun, Ting He, Xin Jin, Jianping Wu, Bin Xu, Guangyuan Zhang, Keyi Wang, Ming Chen
Cancer Management and Research.2021; Volume 13: 6437. CrossRef
Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?
Fatma Bugdayci Basal, Cengiz Karacin, Irem Bilgetekin, Omur Berna Oksuzoglu
Urologia Internationalis.2021; 105(7-8): 666. CrossRef
Post-surgical Regression of Thoracic Metastases After Salvage Lobectomy for Recurrent Renal Cell Carcinoma
Alessia Stanzi, Elena Verzoni, Margherita Ruggirello, Luigi Rolli, Ugo Pastorino
Clinical Genitourinary Cancer.2020; 18(3): e284. CrossRef
Peking University Third Hospital score: a comprehensive system to predict intra-operative blood loss in radical nephrectomy and thrombectomy
Zhuo Liu, Xun Zhao, Hong-Xian Zhang, Run-Zhuo Ma, Li-Wei Li, Shi-Ying Tang, Guo-Liang Wang, Shu-Dong Zhang, Shu-Min Wang, Xiao-Jun Tian, Lu-Lin Ma
Chinese Medical Journal.2020; 133(10): 1166. CrossRef
Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma
Guilherme Nader Marta, Pedro Isaacsson Velho, Renata R. C. Bonadio, Mirella Nardo, Sheila F. Faraj, Manoel Carlos L. de Azevedo Souza, David Q. B. Muniz, Diogo Assed Bastos, Carlos Dzik
Pathology & Oncology Research.2020; 26(4): 2489. CrossRef
The Clinical Significance of Routine Risk Categorization in Metastatic Renal Cell Carcinoma and its Impact on Treatment Decision-Making: A Systematic Review
Shouki Bazarbashi, Abdullah Alsharm, Faisal Azam, Hazem El Ashry, Jamal Zekri
Future Oncology.2020; 16(34): 2879. CrossRef
Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma
Ehab Abdou, Ravi M. Pedapenki, Mohamed Abouagour, Abdul R. Zar, Emad Dawoud, Dalia Elshourbagy, Humaid O. Al-Shamsi, Enrique Grande
Expert Review of Anticancer Therapy.2020; 20(10): 831. CrossRef
Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial
Anup Patel, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, Daniel J. George
Clinical Cancer Research.2020; 26(18): 4863. CrossRef
External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model
Pawel Chrom, Jakub Zolnierek, Lubomir Bodnar, Rafal Stec, Cezary Szczylik
International Journal of Clinical Oncology.2019; 24(5): 526. CrossRef
Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution
Mario Uccello, Tasnim Alam, Haider Abbas, Ajith Nair, Jennifer Paskins, Guy Faust
Clinical Genitourinary Cancer.2019; 17(3): e658. CrossRef
Towards individualized therapy for metastatic renal cell carcinoma
Ritesh R. Kotecha, Robert J. Motzer, Martin H. Voss
Nature Reviews Clinical Oncology.2019; 16(10): 621. CrossRef
The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes
S. Albisinni, D. Pretot, W. Al Hajj Obeid, F. Aoun, T. Quackels, A. Peltier, T. Roumeguère
Progrès en Urologie.2019; 29(8-9): 423. CrossRef
Prognostic Significance of Systemic Inflammatory Response in Patients with Synchronous and Metachronous Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors
Joongwon Choi, Tae Jin Kim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Minyong Kang, Seong Il Seo
The Korean Journal of Urological Oncology.2019; 17(3): 150. CrossRef
The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma
Joanna Huszno, Zofia Kolosza, Jolanta Mrochem-Kwarciak, Tomasz Rutkowski, Krzysztof Skladowski
Oncology.2019; 97(1): 7. CrossRef
Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis
Bo Li, Pingting Zhou, Yujie Liu, Haifeng Wei, Xinghai Yang, Tianrui Chen, Jianru Xiao
Clinica Chimica Acta.2018; 483: 48. CrossRef
Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer
Zhenhua Huang, Yantan Liu, Chen Yang, Xiaoyin Li, Changqie Pan, Jinjun Rao, Nailin Li, Wangjun Liao, Li Lin
BMC Cancer.2018;[Epub] CrossRef
The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis
Xuemin Wang, Shiqiang Su, Yuanshan Guo
Oncotarget.2017; 8(48): 84506. CrossRef

12,295 View
211 Download
29 Web of Science
31 Crossref

Differences in Overall Survival When Colorectal Cancer Patients are Stratified into New TNM Staging Strategy: Ho-Suk Oh, Hyoung-Jung Chung, Hearn-Kook Kim, Jong-Soo Choi; Cancer Res Treat. 2007;39(2):61-64. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.61

Abstract PDF PubReader ePub

Purpose

The purpose of this study is to determine whether the prognosis can be more precisely gauged by the revised 6th AJCC staging system and if this is suitable for Korean colorectal cancer patients, and especially for those patients in the Youngdong district.

Materials and Methods

Between September 1996 and December 2003, 365 patients with histologically confirmed colorectal cancer were analyzed. Kaplan-Meier analyses were used to compare the overall and stage-specific 5-year survival. All the statistical tests were two-sided.

Results

The overall 5-year survival for the entire cohort was 62%. According to the stages defined by the AJCC fifth edition system, the 5-year stage-specific survival was 91% for stage I, 82% for stage II, 51% for stage III and 4% for stage IV. According to the stages defined by the AJCC sixth edition system, the 5-year stage-specific survival was 91% for stage I, 81% for stage IIa, 83% for stage IIb, 100% for stage IIIa, 64% for stage IIIb, 37% for stage IIIc and 4% for stage IV. The 5-year survival was significantly better for the patients with stage IIIb (64%) than those patients with stage IIIc (37%) (p<.001).

Conclusion

It is widely known that the AJCC sixth edition system for colorectal cancer stratifies survival more distinctly than does the fifth edition system by providing more substages. Our study showed that stage IIIb disease had better survival than stage IIIc disease, but we couldn't confirm that this new staging system is relevant in our Korean clinical practice due to the small study population. Therefore, further study is required in a larger population.

Citations

Citations to this article as recorded by

Pathological Characteristics, Prognostic Determinants and the Outcome of Patients Diagnosed with Colorectal Adenocarcinoma at the University Teaching Hospital of Kigali
Delphine Uwamariya, Déogratias Ruhangaza, Belson Rugwizangoga, Antonio Giovanni Solimando
Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1. CrossRef
Estimating short-term and long-term survival in rectal cancer patients using cure model
Behrouz Beiranvand, Shaghayegh Kamian, Robabeh Ghodssi-Ghassemabadi
Journal of Family Medicine and Primary Care.2022; 11(9): 5615. CrossRef
Assessment of prognostic factors in long-term survival of male and female patients with colorectal cancer using non-mixture cure model based on the Weibull distribution
Mehdi Azizmohammad Looha, Elaheh Zarean, Fatemeh Masaebi, Mohamad Amin Pourhoseingholi, Mohamad Reza Zali
Surgical Oncology.2021; 38: 101562. CrossRef
The role of socioeconomic disparity in colorectal cancer stage at presentation
Aesha Patel, Owen Gantz, Pavel Zagadailov, Aziz M. Merchant
Updates in Surgery.2019; 71(3): 523. CrossRef
The effects of time valuation in cancer optimal therapies: a study of chronic myeloid leukemia
Pedro José Gutiérrez-Diez, Miguel Ángel López-Marcos, Julia Martínez-Rodríguez, Jose Russo
Theoretical Biology and Medical Modelling.2019;[Epub] CrossRef
Permanent colostomy wound: Aeromedical disposal
U Bhattacharya, A Kumar, AVK Raju
Indian Journal of Aerospace Medicine.2019; 63: 39. CrossRef
Analyzing the Long-Term Survival of Patients with Colorectal Cancer: A Study Using Parametric Non-Mixture Cure Rate Models
Mehdi Azizmohammad Looha, Elaheh Zarean , Mohamad Amin Pourhoseingholi, Seyyed Vahid Hosseini, Tara Azimi, Soheila Khodakarim
International Journal of Cancer Management.2018;[Epub] CrossRef
Colorectal Cancer in Jordan: Survival Rate and Its Related Factors
Ghazi Faisal Sharkas, Kamal H. Arqoub, Yousef S. Khader, Mohammad R. Tarawneh, Omar F. Nimri, Marwan J. Al-zaghal, Hadil S. Subih
Journal of Oncology.2017; 2017: 1. CrossRef
ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer
Jian-Kang Zhou, Yu-Zhu Zheng, Xue-Sha Liu, Qiheng Gou, Rui Ma, Cheng-Lin Guo, Carlo M. Croce, Lunxu Liu, Yong Peng
Oncotarget.2017; 8(20): 32864. CrossRef
High expression levels of unc-51-like kinase 1 as a predictor of poor prognosis in colorectal cancer
YIFENG ZOU, ZEXIAN CHEN, XIAOWEN HE, XIAOSHENG HE, XIANRUI WU, YUFENG CHEN, XIAOJIAN WU, JIANPING WANG, PING LAN
Oncology Letters.2015; 10(3): 1583. CrossRef
Follow-up After Curative Resection of Colorectal Cancer
Bridget N. Fahy
Annals of Surgical Oncology.2014; 21(3): 738. CrossRef
An overview of colorectal cancer survival rates and prognosis in Asia
Bijan Moghimi-Dehkordi
World Journal of Gastrointestinal Oncology.2012; 4(4): 71. CrossRef

17,029 View
105 Download
12 Crossref

First
Prev
Page of 1
Next
Last

Search